Samuel D. Riccitelli
Chairman and interim President and Chief Executive Officer
Mr. Riccitelli is the Chairman and interim President and Chief Executive Officer of Biocept since February 2022. Mr. Riccitelli has been a member of the Board of Directors of Biocept since October 2020 and Chairman of the Board since July 2021. Mr. Riccitelli has served as a member of the Board of Directors of Orthopediatrics, Inc. (Nasdaq: KIDS) since 2017, a company focused exclusively on the orthopedic implant needs of children. He also served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019, Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc. (Nasdaq: PRPO), a diagnostic services company. From 2012 to 2017, Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas.
Philippe Marchand, Ph.D.
Chief Operating Officer
Dr. Marchand is a veteran biotechnology executive and scientist with a proven track record in transitioning concepts to implementation and completion. Most recently, Dr. Marchand was the Chief Operating Officer of Biosplice Therapeutics, aiding in the development of first-in-class small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Previously, he was the Chief Information Officer of Genoptix, where he oversaw the creation of the company’s diagnostics laboratory, the subsequent IPO, and the acquisition by Novartis. Following the acquisition, he assumed responsibilities for global IT operations for Novartis Oncology. Earlier in his career, Dr. Marchand founded two San Diego-based technology companies, Celula and Parallel Solutions. Dr. Marchand received an MS (Hons), a Ph.D., and the Research Habilitation in Electrical Engineering from the Université de Haute Alsace, France, and was a Lavoisier post-doctoral fellow at the University of California, San Diego.
Director and interim Chief Financial Officer
Mr. Morales is the interim Chief Financial Officer of Biocept and board member, bringing more than 30 years of broad leadership experience in the US and Latin America. He has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, Mazda North America, and McDonald’s. Mr. Morales led the expansion of Citibank’s consumer finance operation into Latin America and most recently served as president and CEO of Apoyo Financiero, Inc. a Community Development Financial Institution (CDFI). Morales has led multiple private equity backed start-up companies. He earned his Bachelor of Science degree in Finance from the University of Southern California and is a licensed CPA.
Michael C. Dugan, M.D.
Senior Vice President, Chief Medical Officer and Medical Director
Dr. Dugan leads our clinical strategic development as CMO and oversees our CAP accredited CLIA clinical laboratory as Medical Director. He is an experienced physician and biotech executive who has directed several major commercial reference laboratories and helped launch numerous novel molecular diagnostic assays and platforms used in oncology, infectious disease and public health applications such as cancer screening, monitoring, diagnosis and therapy selection. Dr. Dugan has held leadership positions with Clinical Genomics, Exact Sciences, Genzyme Genetics (acquired by LabCorp), Quest Diagnostics (including acquired companies AmeriPath and Specialty Laboratories), and UCLA.
A graduate of the University of Notre Dame (B.S. Biology) and University of Arizona College of Medicine (M.D.), he completed his post-graduate medical education in anatomic pathology at Yale-New Haven Hospital and continued training in pathology and laboratory medicine at Children’s Hospital Los Angeles and UCLA. He is board-certified in Anatomic and Clinical Pathology.
Darrell Taylor, Esq.
Senior Vice President, Chief Legal Officer and Chief Compliance Officer
Darrell Taylor brings more than 30 years of healthcare and leadership experience, including over 20 years as a healthcare attorney. He is an experienced attorney who has provided legal regulatory and compliance counsel to global biopharmaceutical companies as well as numerous biotech start-ups. Most recently, Darrell served as Chief Compliance Officer for Precision Diagnostics and its CLIA-certified and CAP-accredited clinical laboratory.
Previous to his in-house positions, Darrell honed his skills as an attorney with the global law firm, DLA Piper, serving healthcare companies, biopharma, private equity, venture capital, institutional investors, and providers by assisting them with navigating opportunities in this highly complex, heavily regulated, and ever-changing industry. Darrell earned his J.D. from the University of Notre Dame Law School and his B.S.M.T., with high honors, at The University of Texas Medical Branch.
Senior Vice President, Corporate Development
Mike Terry is a seasoned veteran in the molecular diagnostics and liquid biopsy industries, Mike has vast leadership experience managing large and small commercial teams. Prior to Biocept, he served as Executive Vice President of Sequenom, Inc., and more recently Trovagene, Inc. He also has held leadership positions at GE Healthcare’s Marquette Medical division, Lumenis Ltd, Aspect Medical Systems Inc. and Ligand Diagnostics.
Mary C. Mathis
Vice President, Finance
Mary C. Mathis has 39 years of experience and is a strategic and results-oriented accounting and finance leader with a proven track record of designing and executing intuitive consultative operating and technical solutions that promote strategy development and process improvement across corporate enterprises while optimizing available financial resources. Her varied industry experience includes Big 4 Public Accounting, bioscience, manufacturing, software development and servicing (SaaS), solar installation and maintenance, loan servicing, manufacturing, construction, distribution, and franchise ownership. She has worked for and provided consultation services for companies ranging in size from the small start up to $1 billion in revenues. She has a Bachelor of Business Administration degree in Accounting from Western Michigan University and obtained her certification in executive financial planning at San Diego State University. She obtained her CPA certification from the state of Texas.
Senior Vice President, Commercial Operations
Dave Karlander leads our sales, marketing and managed care teams and brings over 25 years of experience successfully building and managing major brands in diagnostics, devices, and pharmaceuticals. His previous experience includes executive sales and marketing positions at Exact Sciences and Novartis’ Genoptix Medical Lab, where he led successful campaigns to expand product pipelines, reimbursement rates and sales volumes, among other responsibilities. Dave earned his MBA from Northwestern University’s Kellogg Graduate School of Management, and a Bachelor of Science from Miami University.
Vice President, Sales
Antonio Paternostro brings over 15 years of Sales leadership experience in the clinical diagnostics, anatomic pathology, and biotechnology industries. Antonio served multiple commercial leadership positions at PLUS DX, Miraca Life Sciences and most recently GenomeDx Biosciences (now Decipher Biosciences). Antonio holds a Bachelor of Science degree in Biology and Secondary Education from Central Connecticut State University.